Replies to post #447017 on Amarin Corp Plc (AMRN)

[Sagaponack]

Oh the irony if the SC was to rule in Amarin's favor....the only way we got here was by Hikma appealing. Never let a crisis go to waste. Let's hope justice prevails. Yes, other generics may fill the void but if Hikma is held to have infringed there are damages........

Their actions cannot go unpunished.

[antibluechip]

Rosemount and Saga,

I have one question about the brief. Amarin makes a case by showing the difference between the SH indication and the CV indication. Then, in the following paragraph, they say the Petitioners were not happy with the indication for severe hypertriglyceridemia, but went for Hypertriglyceridemia...(only difference a capital H)

"Because petitioners knew that Vascepa’s overwhelming value was in the CV indication, they were not content
to market their drug lawfully as only a treatment for severe hypertriglyceridemia. Instead, petitioners’ website described their product as a treatment for “Hypertriglyceridemia,” a category that unambiguously encompasses respondents’ patented use." p3

Question: So all Hikma did is capitalize Hypertriglyceridemia? Is Hypertriglyceridemia defined as CV as he says? Isn't there a better term for the CV usage that he could have used? It doesn't support the case for me.
Dave